Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2012
05/18/2012CA2817219A1 Methods of treating cancer
05/18/2012CA2817015A1 Protein complexes for antigen binding and methods of use
05/18/2012CA2816944A1 Compounds useful for inhibiting chk1
05/18/2012CA2816603A1 Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
05/18/2012CA2816601A1 Dexamethasone combination therapy
05/18/2012CA2815916A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferativedisorders
05/18/2012CA2815839A1 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
05/18/2012CA2815492A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
05/17/2012US20120124683 Delivery method
05/17/2012US20120122991 Method for treating cancer by increasing amp-activated kinase activity
05/17/2012US20120122984 Methods of Treating Lipomas and Liposarcomas
05/17/2012US20120122977 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
05/17/2012US20120122972 Novel eicosanoid derivatives
05/17/2012US20120122956 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
05/17/2012US20120122947 Spiro-oxindole mdm2 antagonists
05/17/2012US20120122946 Polymorphisms for predicting disease and treatment outcome
05/17/2012US20120122943 Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents
05/17/2012US20120122937 Methods for inhibiting cancer cell proliferation and inducing cancer cell apoptosis
05/17/2012US20120122934 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
05/17/2012US20120122930 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents
05/17/2012US20120122924 Nampt inhibitors
05/17/2012US20120122910 Method of treating cancer using a survivin inhibitor
05/17/2012US20120122909 Spiro-oxindole compounds and their uses as therapeutic agents
05/17/2012US20120122908 Novel C-4 Substituted Retinoids
05/17/2012US20120122895 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
05/17/2012US20120122894 Inhibitors of bruton's tyrosine kinase
05/17/2012US20120122893 Methods of treating cancer
05/17/2012US20120122892 Chemical compounds
05/17/2012US20120122891 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
05/17/2012US20120122885 Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
05/17/2012US20120122884 Compounds useful as inhibitors of atr kinase
05/17/2012US20120122883 New salts
05/17/2012US20120122882 Substituted Pyrrolo-Pyrimidine Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors
05/17/2012US20120122881 Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety
05/17/2012US20120122879 Compounds useful as protein kinase inhibitors
05/17/2012US20120122869 Trizaole compounds that modulate hsp90 activity
05/17/2012US20120122867 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
05/17/2012US20120122866 Topical pharmaceutical composition including rel-n-[6-[(2r,6s)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
05/17/2012US20120122865 Isoindoline compounds and methods of their use
05/17/2012US20120122862 Arginine derivatives with np-i antagonistic activity
05/17/2012US20120122860 Solid forms of sulfonamides and amino acids
05/17/2012US20120122857 Heterobicyclic carboxamides as inhibitors for kinases
05/17/2012US20120122854 Carbocyclic Fused Cyclic Amines
05/17/2012US20120122849 Pkm2 modulators for use in the treatment of cancer
05/17/2012US20120122847 Aurora kinase modulators and method of use
05/17/2012US20120122842 Nampt and rock inhibitors
05/17/2012US20120122841 Biological Markers Predictive Of Anti-Cancer Response To Insulin-like Growth Factor-1 Receptor Kinase Inhibitors
05/17/2012US20120122840 Compounds and therapeutic uses thereof
05/17/2012US20120122839 Novel pyrrolidin-2-ones
05/17/2012US20120122835 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
05/17/2012US20120122825 Use of picoplatin to treat prostate cancer
05/17/2012US20120122824 Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
05/17/2012US20120122818 Lung-targeted drugs
05/17/2012US20120122807 Cardiac Glycoside Analogs in Combination with Emodin for Cancer Therapy
05/17/2012US20120122804 Substituted quinobenzoxazine analogs
05/17/2012US20120122799 Cyclic peptide antitumor agents
05/17/2012US20120122798 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
05/17/2012US20120122797 Peptidic compound and use of same
05/17/2012US20120122796 Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient
05/17/2012US20120122784 Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
05/17/2012US20120122781 Peptide ligands of somatostatin receptors
05/17/2012US20120122771 STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN
05/17/2012US20120122768 Alginate oligomers for use in overcoming multidrug resistance in bacteria
05/17/2012US20120122765 Compounds and related methods for manipulating parp-1-dependent cell death
05/17/2012US20120122764 Substituted carbamoylcycloalkyl acetic acid derivatives as nep
05/17/2012US20120122763 Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
05/17/2012US20120122762 186 Human Secreted Proteins
05/17/2012US20120122206 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
05/17/2012US20120121741 Water soluble defructosylated pea extract, and use thereof as a prebiotic agent
05/17/2012US20120121721 Skin care products and compositions
05/17/2012US20120121717 DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD
05/17/2012US20120121716 Pharmaceutical composition of an anthracycline
05/17/2012US20120121715 DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
05/17/2012US20120121711 Microsphere drug carrier, preparation method, composition and use thereof
05/17/2012US20120121709 Phase transition biopolymers and methods of use
05/17/2012US20120121699 Lycopene and resveratrol dietary supplement
05/17/2012US20120121695 Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine
05/17/2012US20120121691 Method for Increasing the Production of a Specific ACYL-Chain Dihydroceramide(s) for Improving the Effectiveness of Cancer Treatments
05/17/2012US20120121689 Small interfering rna delivery
05/17/2012US20120121682 cRGD PEPTIDE DERIVATIVE AND ITS MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING A cRGD PEPTIDE DERIVATIVE
05/17/2012US20120121670 Polyarginine nanocapsules
05/17/2012US20120121668 Compositions for oral adminstration of active principles requiring masking of taste
05/17/2012US20120121665 Implantable or insertable medical device resistant to microbial growth and biofilm formation
05/17/2012US20120121654 Nanoparticle isoflavone compositions & methods of making and using the same
05/17/2012US20120121649 Compositions and methods for the prevention and treatment of cancer
05/17/2012US20120121640 OX40/TRAIL Fusion Proteins
05/17/2012US20120121636 Tat-Based Vaccine Compositions and Methods of Making and Using Same
05/17/2012US20120121634 Soluble pd-1 variants, fusion constructs, and uses thereof
05/17/2012US20120121626 Chimeric VEGF Peptides
05/17/2012US20120121622 Biodegradable immunomodulatory formulations and methods for use thereof
05/17/2012US20120121621 Synergistic prebiotic compositions
05/17/2012US20120121618 Predicting And Treating Prostate Cancer
05/17/2012US20120121617 Promoters for recombinant viral expression
05/17/2012US20120121616 Immune balance-regulating agent
05/17/2012US20120121615 Alaninyl maytansinol antibody conjugates
05/17/2012US20120121614 Methods and compositions for bi-specific targeting of cd19/cd22
05/17/2012US20120121612 Fermented wheat germ proteins (fwgp) for the treatment of cancer
05/17/2012US20120121610 Therapeutic agent and assay
05/17/2012US20120121608 Use of sam68 for modulating signaling through the tnf receptor
05/17/2012US20120121606 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
1 ... 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 ... 2211